Sally Arai

BMT specialist, Hematologist

Assistant Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center

Blood and Marrow Transplant Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-723-0822
Learn More About the Clinic Getting Here Make An Appointment

Hematology Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Amyloid Center

  • 300 Pasteur Drive
  • Stanford, CA 94305
  • Phone: 650-725-6186
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Residency: Strong Memorial Hospital (1995) NY

Fellowship: John Hopkins Hospital (1999) MD

Fellowship: Mount Sinai Medical Center (1998) NY

Internship: Strong Memorial Hospital (1993) NY

Medical Education: Dartmouth Medical School (1991) NH

MS, Stanford University, Epidemiology (2006)

MD, Dartmouth Medical School

Honors & Awards

K23-“Reduce GVHD and Relapse using Ex-Vivo Expanded Allogeneic Cell Therapy”, NIH (2003-2008)

“A phase I/II study of post-transplant autologous CIK cells for high-risk hematologic malignancies”, Cancer Treatment Research Foundation (2005-2009)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., & Lowsky, R. (2014). Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(6), 837-843.

Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease
Palmer, J., Williams, K., Inamoto, Y., Chai, X., Martin, P. J., & Lee, S. J. (2014). Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(3), 337-344.

Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis.
Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., & Witteles, R. M. (2014). Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart rhythm , 11(1), 158-162.

Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma.
Weng, W.-K., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., & Kim, Y. H. (2013). Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. Science translational medicine, 5(214), 214ra171-?.

Comorbidity burden in patients with chronic GVHD
Wood, W. A., Chai, X., Weisdorf, D., Martin, P. J., Cutler, C., & Mitchell, S. (2013). Comorbidity burden in patients with chronic GVHD. BONE MARROW TRANSPLANTATION, 48(11), 1429-1436.

Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.
Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., & Liedtke, M. (2013). Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica, 98(10), 1593-1599.

Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium
Treister, N., Chai, X., Kurland, B., Pavletic, S., Weisdorf, D., & Cutler, C. (2013). Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium. BONE MARROW TRANSPLANTATION, 48(8), 1123-1128.

The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis
Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., & Liedtke, M. (2013). The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 161(3), 367-372.

H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease.
Sahaf, B., Yang, Y., Arai, S., Herzenberg, L. A., Herzenberg, L. A., & Miklos, D. B. (2013). H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease. Proceedings of the National Academy of Sciences of the United States of America, 110(8), 3005-3010.

Successful Surgical and Medical Treatment of Rhizopus Osteomyelitis Following Hematopoietic Cell Transplantation
Vashi, N., Avedian, R., Brown, J., & Arai, S. (2012). Successful Surgical and Medical Treatment of Rhizopus Osteomyelitis Following Hematopoietic Cell Transplantation. ORTHOPEDICS, 35(10), E1556-E1561.

Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium
Jacobsohn, D. A., Kurland, B. F., Pidala, J., Inamoto, Y., Chai, X., & Flowers, M. Ed. (2012). Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. BLOOD, 120(13), 2545-2552.

Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels
Tolar, J., Deeg, H. J., Arai, S., Horwitz, M., Antin, J. H., & Anderlini, P. (2012). Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(7), 1007-1011.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., & Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145-6154.

More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis
Stevenson, R., Witteles, R., Damrose, E., Arai, S., Lafayette, R. A., & Liedtke, M. (2012). More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 138(5), 509-511.

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., & Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581-588.

Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma
Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., & Stockerl-Goldstein, K. (2012). Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. BONE MARROW TRANSPLANTATION, 47(4), 516-521.

Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study
Pidala, J., Vogelsang, G., Martin, P., Chai, X., Storer, B., & Lee, S. J. (2012). Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(3), 451-458.

Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2012). Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 31(3), 325-331.

Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., & Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679-1687.

A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies
Chen, G. L., Arai, S., Flowers, M. Ed., Otani, J. M., Qiu, J., & Miklos, D. B. (2011). A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. BLOOD, 118(15), 4070-4078.

Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria
Arai, S., Jagasia, M., Storer, B., Chai, X., Pidala, J., & Lee, S. J. (2011). Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. BLOOD, 118(15), 4242-4249.

Short tandem repeat and human leukocyte antigen mutations or losses confound engraftment and typing analysis in hematopoietic stem cell transplants
Pereira, S., Vayntrub, T., Hiraki, D. D., Cherry, A. M., Arai, S., & Grumet, F. C. (2011). Short tandem repeat and human leukocyte antigen mutations or losses confound engraftment and typing analysis in hematopoietic stem cell transplants. HUMAN IMMUNOLOGY, 72(6), 503-509.

Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen
Schaenman, J. M., Shashidhar, S., Rhee, C., Wong, J., Navato, S., & Brown, J. M. (2011). Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(5), 693-702.

Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium
Pidala, J., Kurland, B., Chai, X., Majhail, N., Weisdorf, D. J., & Lee, S. J. (2011). Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. BLOOD, 117(17), 4651-4657.

Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., & Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192-199.

Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia
Jones, C. D., Arai, S., Lowsky, R., Tyan, D. B., Zehnder, J. L., & Miklos, D. B. (2010). Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 150(5), 637-639.

Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., & Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145-1154.

Rituximab in hematopoietic cell transplantation
Arai, S., & Miklos, D. B. (2010). Rituximab in hematopoietic cell transplantation. EXPERT OPINION ON BIOLOGICAL THERAPY, 10(6), 971-982.

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., & Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099-1109.

High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation
Majhail, N. S., Flowers, M. E., Ness, K. K., Jagasia, M., Carpenter, P. A., & Burns, L. J. (2009). High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 43(1), 49-54.

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
Arai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., & Klingemann, H. (2008). Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. CYTOTHERAPY, 10(6), 625-632.

A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
Kurian, A. W., Newton Thompson, R., Gaw, A. F., Arai, S., Ortiz, R., & Garber, A. M. (2007). A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 25(6), 634-641.

Regulation of OX40 gene expression in graft-versus- host disease
Miura, Y., Thoburn, C. J., Bright, E. C., Arai, S., & Hess, A. D. (2005). Regulation of OX40 gene expression in graft-versus- host disease. TRANSPLANTATION PROCEEDINGS, 37(1), 57-61.

Natural killer cells: can they be useful as adoptive immunotherapy for cancer?
Arai S, & Klingemann H-G. (2005). Natural killer cells: can they be useful as adoptive immunotherapy for cancer?. Expert Opin Biol Ther.

Association of Foxp3 regulatory gene expression and graft-versus-host disease
Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, & Hess AD. (2004). Association of Foxp3 regulatory gene expression and graft-versus-host disease. Blood, 104.

Role of immunotherapy in stem cell transplantation
Arai, S., & Klingemann, H. G. (2003). Role of immunotherapy in stem cell transplantation. INTERNATIONAL JOURNAL OF HEMATOLOGY, 77(1), 22-28.

Poor outcome in steroid refractory GVHD with ATG treatment
Arai S, Margolis J, Zahurak M, Anders V, & Vogelsang GB. (2002). Poor outcome in steroid refractory GVHD with ATG treatment. Biol Blood Marrow Transplant, 8.

Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings
Vogelsang, G. B., & Arai, S. (2001). Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. BONE MARROW TRANSPLANTATION, 27(12), 1255-1262.

von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy
Arai S, Allan C, Streiff M, Hutchins GM, Vogelsang GB, & Tsai HM. (2001). von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. The Hematology Journal, 2.

Management of graft-versus-host disease
Arai, S., & Vogelsang, G. B. (2000). Management of graft-versus-host disease. BLOOD REVIEWS, 14(4), 190-204.